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Abstract: Biohybrid nanosystems represent the cutting-edge research in
biofunctionalization of micro- and nano-systems. Their physicochemical
properties bring along advantages in the circulation time, camouflaging from
the phagocytes, and novel antigens. This is partially a result of the qualitative
differences in the protein corona, and the preferential targeting and uptake in
homologous cells. However, the effect of the cell membrane on the cellular
endocytosis mechanisms and time has not been fully evaluated yet. Here, the
effect is assessed by quantitative flow cytometry analysis on the endocytosis
of hydrophilic, negatively charged porous silicon nanoparticles and on their
membrane-coated counterparts, in the presence of chemical inhibitors of
different uptake pathways. Principal component analysis is used to analyze all
the data and extrapolate patterns to highlight the cell-specific differences in
the endocytosis mechanisms. Furthermore, the differences in the composition
of static protein corona between naked and coated particles are investigated
together with how these differences affect the interaction with human
macrophages. Overall, the presence of the cell membrane only influences the
speed and the entity of nanoparticles association with the cells, while there is
no direct effect on the endocytosis pathways, composition of protein corona,
or any reduction in macrophage-mediated uptake.
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1. Introduction
Cell membrane-wrapped nanoparticles
(NPs) are under investigation in multiple
applications, from vaccines to drug delivery
systems, detoxification systems, and as
cues for proliferation and differentiation
of cells.[1–3] Moreover, these biohybrid
nanosystems present interesting proper-
ties, including prolonged circulation time,
reduced uptake by the mononuclear phago-
cyte system, tissue- and inflammation-
targeting properties.[4–7] These properties
derive both from the molecules decorating
the membrane surface, including carbo-
hydrates (both as cell-specific antigenic
signature and as sialic acid residues), by a
specific lipidic composition in the mem-
brane (important for the right orientation
of the membrane), and by the different pro-
teins constituting the in vivo protein corona
and by their orientation.[8–11] To date, the
cell membrane coating technique has
been successfully applied to nanomaterials
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different in composition, size, charge, and hydrophobicity, rang-
ing from polymeric to gold, silica, porous silicon (PSi) particles,
and to electrospun fibers.[1] One of the main factors influencing
the successful encapsulation of the particles has been identified
in the particles’ surface charge that results in electrostatic inter-
actions between the negatively charged membrane and the par-
ticles, producing aggregates.[12,13] However, other factors, includ-
ing the hydrophobicity of the particles, play a role for an effective
membrane encapsulation.[5,12,14]
Interactions between cells and NPs influence the uptake, as
well as the final intracellular fate of the particle with important
consequences on the therapeutic efficacy.[15,16] Size, composition,
electrostatic properties, shape, and hydrophobicity are amongst
the NP’s properties determining differences in the interaction
with the cells.[15,17,18] The endocytosis mechanisms employed by
NPs depend primarily on the size of the particles and the pres-
ence of aggregates or agglomerates.[19] For example, receptor-
mediated and non-mediated uptake of NPs usually exploits the
clathrin- and caveolin-mediated pathways, while macropinocy-
tosis allows the unspecific uptake of nanoparticles up to
500 nm.[16,19] However, recent works have proposed an increased
uptake by micropinocytosis for organic and particularly biohy-
brid NPs.[20,21] Moreover, the internalization of NPs by the cells
is influenced also by the composition of the protein corona.[22]
The impact of the protein corona on the properties of biohybrid
nanosystems has only recently been evaluated, highlighting
qualitative differences in few key proteins and some quantitative
differences in the percentage of known proteins between tradi-
tional and biohybrid particles.[8] Furthermore, the composition
of the protein corona influences also the NPs interactions with
phagocytes and a different corona composition may explain
the reduced interaction of biohybrid NPs with phagocyes.[23,24]
Nevertheless, the effect of the cell membrane coating on the
NPs’ uptake and protein corona composition has not been fully
evaluated yet.
In recent years the use of zebrafish embryos has started to
challenge the use of rodent models for the preliminary screen-
ing of formulations, enabling a cheaper and high-through put
alternative.[25] This model has provided interesting data in the
formulation of liposomes, but it has never been employed before
to evaluate the circulation profile and interaction with phagocytes
of biohybrid NPs.[26]
PSi micro/nano-particles have been extensively investigated
for drug delivery in the treatment of cancer, diabetes, and car-
diovascular diseases.[27–33] Moreover, the material itself presents
immunomodulatory properties due to the surface modification,
which render it an attractive candidate as nanovaccine platform
for cancer immunotherapy or for autoimmune diseases.[2,12,34]
The coating with cell membrane moieties can thereby improve
the circulation time, slow the recognition by the cells of the
mononuclear phagocyte system, and act as source of antigens
and danger signals.
Here, we compared in different cell lines the endocytic mech-
anisms of conventional (negatively charged and hydrophilic
PSi) and biohybrid NPs in presence of chemical compounds
known to inhibit the endocytic pathways and analyzed the effect
of the different inhibitors by principal component analysis
(PCA). Moreover, we assessed the differences in the composition
of static protein corona when the particles were exposed to
Table 1. Size and zeta potential of TRITC-TOPSi particles and TRITC-TOPSi
particles extruded with the cell membrane derived from different cancer
cell lines. The results are presented as mean ± s.d. (n ≥ 3).
Particles Size [nm] PdI Zeta Potential [mV]
TRITC-TOPSi 191 ± 2 0.104 ± 0.021 −23.5 ± 0.7
TRITC-TOPSi@A549 183 ± 7 0.089 ± 0.016 −29.3 ± 1.4
TRITC-TOPSi@MCF-7 181 ± 9 0.094 ± 0.040 −24.8 ± 1.29
TRITC-TOPSi@MDA-MB-231 178 ± 2 0.057 ± 0.020 −26.6 ± 1.7
TRITC-TOPSi@PC3MM2 182 ± 1 0.085 ± 0.025 −25.5 ± 1.1
human plasma. Unexpected findings in the type of proteins
retained on the cell membrane coated particles prompted us to
compare their uptake in human macrophages and to prelim-
inary evaluate their blood circulation behavior in a Zebrafish
model.[25,26]
2. Results and Discussion
2.1. Physicochemical Characteristics and Cytocompatibility of
Cancer Cell Membrane-Coated Particles
Biohybrid particles were prepared by loading thermally oxi-
dized porous silicon (TOPSi) NPs with tetramethylrhodamine
(TRITC), followed by the extrusion with membranes derived
from different cell lines (A549, MCF-7, MDA-MB-231, and
PC3MM2), representing examples of lung carcinoma, breast
cancer, and prostate cancer. The physical properties of these
systems were then evaluated by dynamic and electrophoretic
light scattering. As presented in Table 1, the extrusion with
cell membranes derived from different cell lines resulted in
particles presenting similar size, polydispersity index (PdI)
and zeta potential. This result was expected, considering the
physicochemical characteristics of TOPSi particles (negatively
charged, hydrophilic, and easily dispersible in aqueous solution)
and the optimal core particle characteristics of a biohybrid
nanosystem.[12,13]
The particles were then imaged by transmission electron
microscopy (TEM) to confirm the membrane wrapping in all the
samples. As shown in Figure 1, there was no influence of the ori-
gin of the cell membrane on the encapsulation process. On the
contrary, the presence of the cell membrane was evident in com-
parison with a TEM image of naked TOPSi particles (Figure S1,
Supporting Information). Figure S2 in the Supporting Informa-
tion shows the general view of the NPs population for all the
samples.
Then, after confirming similar properties for all the particles
formulated from different cell types, the impact of a homolo-
gous cell membrane coating on the cytocompatibility of the sys-
tems was evaluated by measuring the intracellular ATP levels af-
ter 24 h of incubation with the NPs. As shown in Figure 2, the
cytocompatibility of PSi NPs coated with cell membranes in-
creased in all the cell lines tested. In particular, for MDA-MB-
231 and PC3MM2 cells, the naked particles were highly cy-
tocompatible up to 100 and 250 µg mL−1, while the coated
NPs display cell viability values comparable to the control
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Figure 1. TEM images of a) TOPSi@A549, b) TOPSi@MCF-7, c) TOPSi@MBA-MD-231, and d) TOPSi@PC3MM2. The TEM grids containing the
samples were negatively stained with uranyl acetate to highlight the presence of the cell membrane.
(Figure 2a) or to ≈50% of the control (Figure 2d) up to
the highest concentration assessed. In the case of A549 and
MCF-7 cells, TOPSi NPs presented an evident dose−response
toxicity curve, which is shifted towards higher concentration
when the NPs were coated with cell membrane (Figure 2b,c).
The cytocompatibility profile of cell membrane-wrapped PSi
NPs is in line with the results previously reported in other
cells lines.[2,12] The concentration of 50 µg mL−1 was iden-
tified as non-toxic concentration to be used in the following
studies.
2.2. Interactions between the NPs and the Cells
The endocytic mechanisms of naked and cell-membrane coated
PSi NPswere first evaluated by flow cytometry (FCM) in presence
of compounds inhibiting the uptake pathways. Before moving to
the FCM experiment, we determined the IC50 of the compounds
in all the cell lines (Figure S3, Supporting Information) after
4 h of incubation with the four different cancer cell lines. IC80
was also calculated and a concentration lower than the IC80 one
was used in the following studies (concentrations reported in
Table S1 in the Supporting Information). Figure 3 shows the
percentage of cells having NPs associated (A) or taken-up (U)
after 1 or 3 h of incubation. In a previous work, we noticed that
the presence of cancer cell membrane is increasing the uptake
kinetic for oncolytic adenoviruses.[35] Thereby, the time-points of
this experiments were chosen to evaluate any difference in the
initial interaction between the coated or naked TOPSi NPs. The
effects of the different parameters on the uptake of the NPs are
summarized by the heatmap (Figure 3). TOPSi indicates the orig-
inal particles, while TOPSi@CCM indicates particles coated with
homologous cell membrane. As for the association of the parti-
cles with the cells, the map is divided horizontally into two big
clusters, with the cluster on the right half of the heat-map clearly
showing the higher percentage of association compared with the
actual uptake, with higher percentage of positive cells for TOPSi 3
h association (T 3A), TOPSi 1 h association (T 1A), TOPSi@CCM
3 h association (TC 3A) and TOPSi@CCM 1 h association (TC
1A) compared to the same samples after fluorescence quenching
with trypan blue (TOPSi 3 h uptake -T 3U-, TOPSi 1 h uptake -T
1U-, TOPSi@CCM 3 h uptake -TC 3U-, TOPSi@CCM 1 h
uptake -TC 1U). Particularly, the presence of the cell membrane
seemed to facilitate the association at earlier time point (1 h),
as shown by the red and white colors in the column of TC 1A.
Furthermore, the results suggested an independence of the
association from the presence of the inhibitors of the endocy-
tosis in solution (e.g., the data referring to chlorpromazine and
3-methyl-𝛽-cyclodextrin in A549 and PC3MM2). Focusing on the
uptake at +37 °C, MDA-MB-231 cells (37-231-MDA-MB-231) up-
taked more NPs compared to the other cancer cell lines (in order
from higher to lowest uptake, MDA-MB-231, PC3MM2, A549,
and MCF-7), with a time-dependent increase in the fraction of
positive cells. In particular, the presence of the homologous
cell membrane increased the fraction of particles taken-up,
when compared to the naked TOPSi NPs (TC 3U vs T 3U for
MDA-MB-231). Previous experiments with particles coated
with cell membrane derived from patient-derived xenografts
hypothesized the presence of tumor proteins (like galectin-3 and
carcinoembryonic antigens) that modulate the interaction with
an homologous cancer cell.[36] Alternatively, the role of tumor
associated carbohydrate antigens is still investigated as potential
source for the enhanced interactions between homologous cell
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Figure 2. Cell viability (%) of a) MDA-MB-231, b) A549, c) MCF-7, and d) PC3MM2 cancer cells after 24 h incubation with TOPSi or TOPSi wrapped with
homologous cell membranes at different concentrations. Fetal bovine serum (10%) medium and Triton X-100 1% are the negative and positive controls,
respectively. The results were normalized to the negative control and are presented as mean ± s.d. (n = 4). The data were analyzed with two-way ANOVA,
followed by Bonferroni’s post-test to evaluate the differences between coated and uncoated NPs. The levels of significance were set at the probabilities
of **p < 0.01 and *** p < 0.001.
membranes.[37] The endocytosis was greatly reduced for cells
incubated in cold (all the samples marked with “ice”), identifying
the need for energy in an active endocytosis, as suggested also
by the size of the NPs.[38] The endocytic pathway of TOPSi NPs
(columns T 3U and T 1U) appeared to be influenced by the pres-
ence of chlorpromazine, sucrose and 3-methyl-𝛽-cyclodextrin,
suggesting a clathrin mediated pathway. The presence of the cell
membrane (columns TC 3U and TC 1U) increased the uptake in
all the condition assessed, except for genistein, suggesting a role
of caveolin and lipid rafts in the endocytosis and fusion of the
membrane-enveloped particles.[39,40] Finally, the data showed a
cell-dependent endocytotic profile of the particles, as previously
demonstrated for other type of NPs.[40,41]
Then, to identify similarities and differences in the uptake pro-
file of the nanosystems based on cell line and inhibitor of the
uptake, we analysed the data presented in the heat-map by PCA
(Figure 4). This kind of analysis has been used to identify similar
clusters of data in different contexts.[42–45] Data were analysed by
PCA using the Python Library Scikit-learn (the related code can
be found as Python Jupiter Notebook as separate file in the Sup-
porting Information). Figure 4a shows that the majority of the
data identifying the different cells lines in presence of different
inhibitors of the uptake clustered together highlighting few ele-
ments being outside the confidence ellipses, which identify the
68% (1𝜎) or 95% (2𝜎) of the values. The ellipses account for 1 or
2 standard deviations from the mean. The elements outside the
confidence interval identified the cluster formed by the values of
uptake of the NPs by 231 cells at +37 °C together with the lack
of effect of chlorpromazine in A549 (first cluster from the top on
the vertical clustering in the heatmap). As for chlorpromazine
in PC3MM2 cells, these data were within the bigger cluster of
data, which did not include 231 at +37 °C and chlorpromazine in
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Figure 3. Heat-map displaying the mechanism of endocytosis of biohybrid nanoparticles. Cells (A549, A; MCF-7, M; MDA-MB-231, 231; PC3MM2, P)
were incubated with different selective inhibitors of specific uptake mechanisms (i.e., ice, chlorpromazine, sucrose, indomethacin, nocodazol, genistein,
and 3-methyl-𝛽-cyclodextrin) and with fluorescently modified coated and uncoated particles (50 µg mL−1) for 1 and 3 h. The samples were run into
FCM to determine the fraction of particles associated before quenching the fluorescence with trypan blue and then run again in FCM. The results are
presented as the mean of 3 samples (TC, TOPSi@CCM; T, TOPSi; A, Associated; U, Uptaken; 1, 1 h; 3, 3 h).
A549, but was separated from the othermain cluster at the follow-
ing node. Moreover, a second PCA, performed on the transposed
dataset (evaluating the covariance of the type of particles, effect of
quenching with trypan blue, and the incubation time), suggested
that the cellular uptake was dependent on the interaction time
and on the type of NP’s surface, while the association was mainly
influenced by the NP’s surface (Figure 4b). These observations
are based on the relative clustering of the different samples, with
all the samples identified with U (uptake) clustering close to each
other in PC1 and PC2 axis (except for TC 3U), while the samples
identified with A clustered differently on PC2 axis depending of
the incubation time, with a clear difference between naked and
membrane-coated particles. The position of TC 3U in the plot
suggested an effect of the surface coating with cell membrane on
the uptake, while this effect was not seen at shorter time points
(T 1 and TC 1 cluster together). Overall, the analysis of the data
with heatmap and PCA suggests that the interactions between
the cells and the particles is active and the uptake mechanism
is cell-dependent, but generally clathrin-mediated with an influ-
ence of caveolin for the cell membrane-coated NPs.
In order to visually confirm the results obtained in FCM, the
interaction between the NPs and the cells was imaged by con-
focal microscopy in the most interesting cases (A549 cells in
selected conditions). Images of A549 cells incubated with the
particles at +37 °C (Figure S4, Supporting Information) did not
clearly present higher interaction for the cell membrane-coated
NPs. Nevertheless, the interaction between the NPs and the cells
was limited in the all the samples, due to the hydrophilic, nega-
tively charged surface of the NPs, with only a mild effect of the
cell membrane coating. The incubation with chlorpromazine re-
duced the interaction between the samples and the cells (as ob-
served also in the quantitative analysis). As shown in Figure S5
in the Supporting Information, there was no effect of the cell
membrane on the interaction between the cells and the NPs. The
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Figure 4. a) PCA of the effect of the coating with cell membrane on the uptake mechanisms of PSi NPs in different cells, in presence of uptake inhibitors.
b) PCA of the transposed dataset to identify the effect of type of particle on association and uptake. The data were analyzed by PCA using Python Scikit-
learn. The code can be found as separate Python Jupiter Notebook file in the Supporting Information.
confocal images of A549 cells incubated with sucrose confirmed
the influence of the clathrin-mediated endocytosis mechanisms
on the uptake of both TOPSi and membrane-coated NPs (Figure
S6, Supporting Information). Finally, we also evaluated the up-
take of the NPs in presence of 3-methyl-𝛽-cyclodextrin (Figure
S7, Supporting Information). The inhibition of the pinocytosis
resulted in an inhibition of the NPs association with A549 cells.
The presence of the cell membrane negatively influenced the as-
sociation.
2.3. Protein Corona and Macrophage Uptake
One important variable interfering with the interactions between
cell and NPs is the protein corona forming on the outer sur-
face of the NPs upon immersion in a physiological fluid (e.g.,
plasma and extracellular matrix).[46] This phenomenon has been
extensively investigated for different types of NPs over the years
and for biohybrid vesicles (leukosomes),[8,22] but it has not been
evaluated yet in presence of a biohybrid particle shielded with
a layer of a cancer cell membrane. Some studies suggest that
the prolonged circulation and stealth effect associated with can-
cer cell membrane-coated particles are associated with the cell
membrane composition in lipids and proteins, with marginal fo-
cus on the circulatory or cytoplasmic protein coronas and their
compositions.[47,48] Therefore, in this study we sought to evalu-
ate the static protein corona after incubation in human plasma
for 1 h (the “hard” corona) for both the naked and cancer cell
membrane (A549)-coated NPs by mass spectrometry.
The Venn diagram presented in Figure 5a provides a visual
summary of the qualitative protein corona composition. In
particular, 88 proteins were found in all the samples, including
the plasma supernatants. Naked and membrane-coated NPs
shared additional 24 hits, with CCM-coated particles present-
ing 7 unique hits and TOPSi’s corona presenting 18 unique
hits. However, the heat-map in Figure 5b clearly depicts the
differences in the corona composition between the two types of
particles. From the results, it was possible to identify three bigger
clusters of proteins: cluster 1 (whose composition is reported
in Table S2 in the Supporting Information) was particularly
enriched in the sample uncoated, with some few common
proteins identified by cluster 4. On the contrary, cluster 2 was
slightly positive for the CCM-coated particles and negative for
the uncoated ones (composition in Table S4 in the Supporting
Information) with cluster 3 (composition in Table S5 in the
Supporting Information) highly positive for the CCM-particles
and negative for TOPSi NPs alone. The hits identified in cluster 2
included some mRNA contaminants, together with complement
factor H related protein, a component of the protein corona
shown to prevent the activation of the complement. Cluster 3
contained proteins commonly expressed on the CCM or involved
in cytoskeleton and membrane adhesion (e.g., cadherin 1 and
myosin 9) with the complement component C8 gamma chain
as protein corona component present only on CCM-coated
NPs. The proteins identified within cluster 1 included the
common constituents of hard protein corona in vitro, including
fibrinogen, apolipoproteins, coagulation factors, thrombin and
other proteins related with the coagulation.[49] In a previous
study conducted on hydrophobic THCPSi NPs before and after
modification with hydrophobin, THCPSi NPs did not bind to
apolipoproteins before modification, contrary to the results with
hydrophilic TOPSi.[50] The binding of fibrinogen and other
coagulation factors has been correlated with uptake by neu-
trophils and their subsequent activation, with an inflammatory
response.[51] Interestingly, the only differences amongst the
particles (Table S2, Supporting Information) included proteins,
like carboxypeptidase, commonly found in the protein corona
surrounding silica particles.[52] These results were mirrored by
the proteic composition of the supernatants, both in comparison
with the relative NPs and between each other (Figures S8–S10,
Supporting Information). Overall, as shown in Figure S11 in the
Supporting Information, the majority of the proteins found in
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Figure 5. Mass spectrometry analysis of the composition of static protein corona. a) Venn diagram summarizing the total protein hits for each of the
samples (TOPSi, TOPSi@CCM, and their respective plasma supernatants) and identifying the number of sample-exclusive or common hits. b) Heat-
map illustrating the differences in the protein corona composition between naked (TOPSi) and membrane-coated (TOPSi@CCM) NPs. Red identifies
positive events, while blue hits not found. The numbered squares correspond to the lists of identified proteins presented in the Supporting Information.
The TOPSi@CCM NPs evaluated in this study were coated with A549 CCM.
Figure 6. Interactions between KG-1 human macrophages and TOPSi (T) or TOPSi@A549 (TC), at the concentration of 50 µg mL−1, after 1 or 3 h of
incubations. The data are presented as mean ± s.d. (n = 3). The results were analyzed by one-way ANOVA followed by Tukey’s multiple comparison.
The levels of significance were set at the probability of *p < 0.05 and **p < 0.01.
the corona of the two particles are implicated in the activation
of the complement or in interaction with lipids (like apolipopro-
teins). Thereby, the results suggest that there are no differences
in the composition of the static protein corona in vitro which
may justify the prolonged circulation of biohybrid NPs.
Based on the results from the protein corona analysis, we
evaluated the interaction of A549 cell membrane-coated particles
(TC) or TOPSi alone (T) by human macrophages. The mean flu-
orescent intensity (Figure 6a) confirmed the presence of a time-
dependent interaction for both particles, despite the high per-
centage of positive events in all the samples (Figure 6b).
In different works, the interaction with the macrophages is
evaluated cross species (murine macrophages with human cell
membrane coating) or still displays interaction between particles
and cells, though at lower extent compared to uncoated particles
and liposome coated particles.[53,54] Moreover, the interaction is
evaluated on adherent macrophages where the sedimentation of
the nanosystems will contribute to their uptake. In this work, we
evaluated the uptake by human macrophages in suspension, in
conditions better mimicking the in vivo conditions. The results
suggested an effect on the association for shorter time points
(1 h), which however is reduced by increasing the incubation
time (3 h). Nevertheless, the percentage of positive events was
over 95% for all the samples, with non-significant or minimally
significant differences amongst the samples.
These NPs were further injected into Zebrafish to evaluate
their circulation profile and the interaction with macrophages
in vivo. The preliminary results shown in Figure S12 in the
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Supporting Information indicated that theNPs coatedwith CCM,
independently from the source of the membrane, tended to ag-
gregate more than the naked NPs. The aggregation played a role
also in the enhanced interaction of CCM-coated particles with
macrophages. Both at 1 and 24 h post-injection, the qualitative re-
sults suggested that biohybrid NPs displayed higher interaction
with macrophages, as shown by bright agglomerates of NPs in
the venous part of the zebrafish vasculature.[26] Further quantita-
tive studies of interaction with the cells of the reticuloendothelial
system and in vivo protein corona composition inmurinemodels
are needed to fully evaluate the contribution of CCMwrapping on
the biodistribution of the nanosystems and their interaction with
the cells of the innate immune system.
3. Conclusion
The effect of the cellmembrane-layer on the interactions between
negatively charged PSi NPs and cancer cell lines was evaluated in
vitro. First, the wrapping of NPs with biohybrid cell membrane-
derived moieties enhanced the cytocompatibility of the NPs in all
the cell lines assessed. The association of the NPs to all the cell
lines was improved when the NPs were coated with homologous
cell membrane. This higher association of the NPs increased also
the percentage of NPs taken-up after 3 h, when compared to the
naked NPs. The endocytosis was proved to be cell line-dependent
with different cell lines showing different susceptibility to the
inhibition of specific pathways and not to be influenced by the
type of cell membrane coating. Cell membrane-coated NPs were
taken-up according to the same mechanisms of the naked NPs,
with a major role played by clathrin-mediated endocytosis and
micropinocytosis. The profile of the corona for both naked and
cell membrane-coated particles was similar and resembled the
profile of conventional NPs. Moreover, the presence of a cancer
cell membrane wrapping had no effect on the percentage of
positive events in human macrophages in suspension when
compared to the naked NPs, while a lower interaction at shorter
incubation points (1 h) could be observed from the analysis of
the MFI. On the contrary, the coating with cell membrane in-
creased the aggregation and the interaction with macrophages in
a Zebrafish model, reducing the circulation time. However, the
interaction of cancer cell membrane-coated NPs with cells of the
innate immune system should be further evaluated in murine
models for the mechanisms governing the enhanced homotopic
accumulation in the tumors after intravenous injection, paying
attention to different diseases models and animal characteris-
tics (e.g., sex, age, weight), in order to have a more insightful
indication of the potential of the biohybrid NPs in cancer therapy.
4. Experimental Section
The detailed description of the experiments performed in this
work can be found from the Supporting Information.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
Acknowledgements
F.F. and O.K.K. acknowledge the Drug Research Program Joint Grant.
S.S. is thankful for support of the “Stiftung zur Förderung des phar-
mazeutischen Nachwuchses in Basel” and the “Freiwillige Akademische
Gesellschaft Basel.” Zebrafish embryos were provided by the research
group of Prof. M. Affolter at Biozentrum Basel. H.A.S. acknowledges fi-
nancial support from the HiLIFE Research Funds, the Sigrid Jusélius Foun-
dation, and the H2020 European Research Council Grant (Grant No.
825020). The authors also acknowledge the following core facilities funded
by Biocenter Finland: Electron Microscopy Unit for TEM and the Light
Microscopy Unit of the Institute of Biotechnology for the confocal micro-
scope.
Conflict of Interest
The authors declare no conflict of interest.
Keywords
biohybrids, cancer cell membranes, nanoparticles, protein corona,
nanoparticle uptake
Received: April 1, 2020
Revised: July 6, 2020
Published online:
[1] R. H. Fang, A. V. Kroll, W. Gao, L. Zhang, Adv. Mater. 2018, 30,
1706759.
[2] F. Fontana, M.-A. Shahbazi, D. Liu, H. Zhang, E. Mäkilä, J. Salonen,
J. T. Hirvonen, H. A. Santos, Adv. Mater. 2017, 29, 1603239.
[3] R. H. Fang, C.-M. J. Hu, B. T. Luk, W. Gao, J. A. Copp, Y. Tai, D. E.
O’connor, L. Zhang, Nano Lett. 2014, 14, 2181.
[4] R.Molinaro, C. Corbo, J. O.Martinez, F. Taraballi, M. Evangelopoulos,
S. Minardi, I. K. Yazdi, P. Zhao, E. De Rosa,M. B. Sherman, A. De Vita,
N. E. Toledano Furman, X. Wang, A. Parodi, E. Tasciotti, Nat. Mater.
2016, 15, 1037.
[5] A. Parodi, N. Quattrocchi, A. L. Van De Ven, C. Chiappini, M. Evan-
gelopoulos, J. O. Martinez, B. S. Brown, S. Z. Khaled, I. K. Yazdi, M.
V. Enzo, L. Isenhart, M. Ferrari, E. Tasciotti, Nat. Nanotechnol. 2013,
8, 61.
[6] C.-M. J. Hu, R. H. Fang, K.-C. Wang, B. T. Luk, S. Thamphiwatana, D.
Dehaini, P. Nguyen, P. Angsantikul, C. H. Wen, A. V. Kroll, C. Carpen-
ter, M. Ramesh, V. Qu, S. H. Patel, J. Zhu, W. Shi, F. M. Hofman, T. C.
Chen, W. Gao, K. Zhang, S. Chien, L. Zhang, Nature 2015, 526, 118.
[7] L. Rao, L.-L. Bu, B. Cai, J.-H. Xu, A. Li, W.-F. Zhang, Z.-J. Sun, S.-S.
Guo, W. Liu, T.-H. Wang, X.-Z. Zhao, Adv. Mater. 2016, 28, 3460.
[8] C. Corbo, R. Molinaro, F. Taraballi, N. E. Toledano Furman, K. A. Hart-
man, M. B. Sherman, E. De Rosa, D. K. Kirui, F. Salvatore, E. Tasciotti,
ACS Nano 2017, 11, 3262.
[9] D. Walczyk, F. B. Bombelli, M. P. Monopoli, I. Lynch, K. A. Dawson, J.
Am. Chem. Soc. 2010, 132, 5761.
[10] D. M. Beckwith, M. Cudic, Semin. Immunol. 2020, 47, 101389.
[11] X. Liang, X. Ye, C. Wang, C. Xing, Q. Miao, Z. Xie, X. Chen, X. Zhang,
H. Zhang, L. Mei, J. Controlled Release 2019, 296, 150.
[12] F. Fontana, S. Albertini, A. Correia, M. Kemell, R. Lindgren, E. Mäkilä,
J. Salonen, J. T. Hirvonen, F. Ferrari, H. A. Santos, Adv. Funct. Mater.
2018, 28, 1801355.
[13] B. T. Luk, C.-M. Jack Hu, R. H. Fang, D. Dehaini, C. Carpenter, W. Gao,
L. Zhang, Nanoscale 2014, 6, 2730.
[14] R. Li, Y. He, S. Zhang, J. Qin, J. Wang, Acta Pharm. Sin. B 2018, 8, 14.
Adv. Healthcare Mater. 2020, 2000529 2000529 (8 of 9) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.advhealthmat.de
[15] S. Behzadi, V. Serpooshan, W. Tao, M. A. Hamaly, M. Y. Alkawareek,
E. C. Dreaden, D. Brown, A. M. Alkilany, O. C. Farokhzad, M. Mah-
moudi, Chem. Soc. Rev. 2017, 46, 4218.
[16] E. Polo, M. Collado, B. Pelaz, P. Del Pino, ACS Nano 2017, 11, 2397.
[17] L. Zhang, Q. Feng, J. Wang, S. Zhang, B. Ding, Y. Wei, M. Dong, J.-Y.
Ryu, T.-Y. Yoon, X. Shi, J. Sun, X. Jiang, ACS Nano 2015, 9, 9912.
[18] R. Liu, W. Jiang, C. D. Walkey, W. C. W. Chan, Y. Cohen, Nanoscale
2015, 7, 9664.
[19] N. Oh, J. H. Park, Int. J. Nanomed. 2014, 9 Suppl 1, 51
[20] T. K. Kaiser, M. Khorenko, A. Moussavi, M. Engelke, S. Boretius, C.
Feldmann, H. M. Reichardt, J. Controlled Release 2020, 319, 360.
[21] S. Zhou, Y. Huang, Y. Chen, S. Liu, M. Xu, T. Jiang, Q. Song, G. Jiang,
X. Gu, X. Gao, J. Chen, Biomaterials 2020, 235, 119795.
[22] C. Corbo, R.Molinaro, A. Parodi, N. E. Toledano Furman, F. Salvatore,
E. Tasciotti, Nanomedicine 2016, 11, 81.
[23] V. Mirshafiee, R. Kim, S. Park, M.Mahmoudi, M. L. Kraft, Biomaterials
2016, 75, 295.
[24] H. Wang, Y. Liu, R. He, D. Xu, J. Zang, N. Weeranoppanant, H. Dong,
Y. Li, Biomater. Sci. 2020, 8, 552.
[25] S. Sieber, P. Grossen, J. Bussmann, F. Campbell, A. Kros, D. Witzig-
mann, J. Huwyler, Adv. Drug Delivery Rev. 2019, 151, 152.
[26] S. Sieber, P. Grossen, P. Uhl, P. Detampel, W. Mier, D. Witzigmann,
J. Huwyler, Nanomed. Nanotechnol. 2019, 17, 82.
[27] J. P. Martins, D. Liu, F. Fontana, M. P. A. Ferreira, A. Correia, S.
Valentino, M. Kemell, K. Moslova, E. Mäkilä, J. Salonen, J. Hirvo-
nen, B. Sarmento, H. A. Santos, ACS Appl. Mater. Interfaces 2018, 10,
44354.
[28] J. P. Martins, R. D’auria, D. Liu, F. Fontana, M. P. A. Ferreira, A. Cor-
reia, M. Kemell, K. Moslova, E. Mäkilä, J. Salonen, L. Casettari, J. Hir-
vonen, B. Sarmento, H. A. Santos, Small 2018, 14, 1800462.
[29] W. Li, Z. Liu, F. Fontana, Y. Ding, D. Liu, J. T. Hirvonen, H. A. Santos,
Adv. Mater. 2018, 30, 1703740.
[30] F. Araújo, N. Shrestha, M. J. Gomes, B. Herranz-Blanco, D. Liu, J. J.
Hirvonen, P. L. Granja, H. A. Santos, B. Sarmento, Nanoscale 2016,
8, 10706.
[31] M. P. A. Ferreira, S. Ranjan, A. M. R. Correia, E. M. Mäkilä, S. M.
Kinnunen, H. Zhang, M.-A. Shahbazi, P. V. Almeida, J. J. Salonen, H.
J. Ruskoaho, A. J. Airaksinen, J. T. Hirvonen,H. A. Santos,Biomaterials
2016, 94, 93.
[32] A. Correia, M.-A. Shahbazi, E. Mäkilä, S. Almeida, J. Salonen, J. Hir-
vonen, H. A. Santos, ACS Appl. Mater. Interfaces 2015, 7, 23197.
[33] J. Wolfram, H. Shen, M. Ferrari, J. Controlled Release 2015, 219, 406.
[34] M.-A. Shahbazi, T. D. Fernández, E. M. Mäkilä, X. Le Guével, C. May-
orga, M. H. Kaasalainen, J. J. Salonen, J. T. Hirvonen, H. A. Santos,
Biomaterials 2014, 35, 9224.
[35] M. Fusciello, F. Fontana, S. Tähtinen, C. Capasso, S. Feola, B.Martins,
J. Chiaro, K. Peltonen, L. Ylösmäki, E. Ylösmäki, F. Hamdan, O. K.
Kari, J. Ndika, H. Alenius, A. Urtti, J. T. Hirvonen, H. A. Santos, V.
Cerullo, Nat. Commun. 2019, 10, 5747.
[36] L. Rao, G.-T. Yu, Q.-F. Meng, L.-L. Bu, R. Tian, L.-S. Lin, H. Deng, W.
Yang, M. Zan, J. Ding, A. Li, H. Xiao, Z.-J. Sun, W. Liu, X. Chen, Adv.
Funct. Mater. 2019, 29, 1905671.
[37] L. Cai, Z. Gu, J. Zhong, D. Wen, G. Chen, L. He, J. Wu, Z. Gu, Drug
Discovery Today 2018, 23, 1126.
[38] Y. Jiang, S. Huo, T. Mizuhara, R. Das, Y.-W. Lee, S. Hou, D. F. Moyano,
B. Duncan, X.-J. Liang, V. M. Rotello, ACS Nano 2015, 9, 9986.
[39] Z. Luo, K. Cai, Y. Hu, B. Zhang, D. Xu, Adv. Healthcare Mater. 2012,
1, 321.
[40] T. Dos Santos, J. Varela, I. Lynch, A. Salvati, K. A. Dawson, PLoS One
2011, 6, 24438.
[41] D. A. Kuhn, D. Vanhecke, B. Michen, F. Blank, P. Gehr, A. Petri-Fink,
B. Rothen-Rutishauser, Beilstein J. Nanotechnol. 2014, 5, 1625.
[42] J. R. Heath, A. Ribas, P. S. Mischel,Nat. Rev. Drug Discovery 2016, 15,
204.
[43] I. T. Jolliffe, J. Cadima, Philos. Trans. R. Soc., A 2016, 374, 20150202.
[44] C. Meng, O. A. Zeleznik, G. G. Thallinger, B. Kuster, A. M. Gholami,
A. C. Culhane, Briefings Bioinf. 2016, 17, 628.
[45] J. Lever, M. Krzywinski, N. Altman, Nat. Methods 2017, 14, 641.
[46] G. Caracciolo, O. C. Farokhzad, M. Mahmoudi, Trends Biotechnol.
2017, 35, 257.
[47] H. Li, K. Jin, M. Luo, X. Wang, X. Zhu, X. Liu, T. Jiang, Q. Zhang, S.
Wang, Z. Pang, Cells 2019, 8, 881.
[48] D. Nie, Z. Dai, J. Li, Y. Yang, Z. Xi, J. Wang, W. Zhang, K. Qian, S. Guo,
C. Zhu, R. Wang, Y. Li, M. Yu, X. Zhang, X. Shi, Y. Gan, Nano Lett.
2020, 20, 936.
[49] A. Amici, G. Caracciolo, L. Digiacomo, V. Gambini, C. Marchini, M.
Tilio, A. L. Capriotti, V. Colapicchioni, R. Matassa, G. Familiari, S.
Palchetti, D. Pozzi, M.Mahmoudi, A. Laganà, RSC Adv. 2017, 7, 1137.
[50] M. Sarparanta, L. M. Bimbo, J. Rytkönen, E. Mäkilä, T. J. Laaksonen,
P. Laaksonen, M. Nyman, J. Salonen, M. B. Linder, J. Hirvonen, H. A.
Santos, A. J. Airaksinen,Mol. Pharmaceutics 2012, 9, 654.
[51] S. Keshavan, P. Calligari, L. Stella, L. Fusco, L. G. Delogu, B. Fadeel,
Cell Death Dis. 2019, 10, 569.
[52] A. Solorio-Rodríguez, V. Escamilla-Rivera, M. Uribe-Ramírez, A.
Chagolla, R. Winkler, C. M. García-Cuellar, A. De Vizcaya-Ruiz,
Nanoscale 2017, 9, 13651.
[53] Q. Feng, X. Yang, Y. Hao, N. Wang, X. Feng, L. Hou, Z. Zhang, ACS
Appl. Mater. Interfaces 2019, 11, 32729.
[54] H. Sun, J. Su, Q. Meng, Q. Yin, L. Chen, W. Gu, P. Zhang, Z. Zhang,
H. Yu, S. Wang, Y. Li, Adv. Mater. 2016, 28, 9581.
Adv. Healthcare Mater. 2020, 2000529 2000529 (9 of 9) © 2020 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
